Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹2,387 Cr revenue.
COGS 45.3%, employees 10.5%.
“EBITDA margin for the quarter was 36.”
“we want to continue to guide to a high single digit growth you know, for next year as well.”
“expect high single digit revenue growth for FY 'twenty six, driven by strong and profitable expansion across our diversified non GPL segment and the continued ramp up of CDMO projects.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 16.9%▲ | 10.5% |
| ROCE | 21.8%▲ | 13.8% |
| Net Margin | 21.6%▲ | 8.7% |
| EBITDA Margin | 31.9%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
Revenue segment breakdown not available.
| (₹ Cr) | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | ₹2,387 Cr +4.5% | ₹2,283 Cr +5.6% | ₹2,161 Cr +1.8% | ₹2,123 Cr |
| Other Income | ₹35 Cr +187.1% | ₹12 Cr -58.4% | ₹29 Cr +96.9% | ₹15 Cr |
| Total Income | ₹2,421 Cr +5.5% | ₹2,295 Cr +4.8% | ₹2,190 Cr +2.4% | ₹2,138 Cr |
| COGS | ₹1,081 Cr +7.9% | ₹1,002 Cr -1.2% | ₹1,014 Cr -2.8% | ₹1,043 Cr |
| ₹1,767 Cr +6.2% | ₹1,664 Cr +6.6% | ₹1,562 Cr -0.7% | ₹1,573 Cr | |
| Profit Before Tax | ₹654 Cr +3.6% | ₹631 Cr +0.4% | ₹629 Cr +11.3% | ₹565 Cr |
| ₹169 Cr +5.1% | ₹160 Cr -0.8% | ₹162 Cr +10.6% | ₹146 Cr | |
| Net Profit | ₹486 Cr +3.1% | ₹471 Cr +0.8% | ₹467 Cr +11.5% | ₹419 Cr |
| Other Comprehensive Income | (₹1 Cr) +77.2% | (₹5 Cr) | (₹0.29 Cr) ↓ Decline | ₹0.10 Cr |
| EPS | ₹39.63 | ₹38.43 | ₹38.11 | ₹34.17 |
| Diluted Shares | ₹12 Cr | ₹12 Cr | ₹12 Cr | ₹12 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Alivus Life Sciences Limited has informed the Exchange about Transcript of Earnings Call.
Alivus Life Sciences Limited has informed the Exchange about Schedule of Investors/Analyst Meeting.
Alivus Life Sciences Limited has informed the Exchange about Link of Earnings Call Recording
Alivus Life Sciences Limited has informed the Exchange about Schedule of meet - Earnings Call.
Alivus Life Sciences Limited has informed the Exchange about General Updates
Alivus Life Sciences Limited has informed the Exchange about Schedule of Analyst / Institutional Investor meeting.
Alivus Life Sciences Limited has informed the Exchange about Schedule of Analyst/Institutional Investor meetings
Alivus Life Sciences Limited has informed the Exchange about General Updates
Alivus Life Sciences Limited has informed the Exchange about Schedule of meet
Alivus Life Sciences Limited has informed the Exchange about Transcript of Earnings Call
Alivus Life Sciences Limited has informed the Exchange about General Updates
Alivus Life Sciences Limited has informed the Exchange about Schedule of Analyst/Institutional Investor meetings.
Alivus Life Sciences Limited has informed the Exchange about Link of Recording of Earnings Call
Alivus Life Sciences Limited has informed the Exchange about Investor Presentation
Alivus Life Sciences Limited has informed the Exchange regarding a press release dated January 22, 2026, titled "Press Release on Unaudited Financial Results of the Company for the Third Quarter and N...